Additionally, it should be noted that the absence of an E2 effect on ER+ tumor cell dissemination to bone confirms previous reports[20,27] and is consistent with the clinical observation of similar incidences of bone micrometastases in clinical series of patients with ER+ or ER− breast cancers[77–80]. Here, ESR1 is linked to breast cancer.